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Static and dynamic hyperinflation during severe 
acute exacerbations of chronic obstructive 
pulmonary disease
Wouter h van geffen1,2
huib aM Kerstjens2
1Department of respiratory Medicine, 
Medical Centre leeuwarden, 
leeuwarden, the netherlands; 
2Department of Pulmonary Diseases, 
University of Groningen, University 
Medical Center Groningen, 
Groningen, the Netherlands
Background: Static hyperinflation is known to be increased during moderate acute exacerbations 
of chronic obstructive pulmonary disease (COPD) (AECOPD), but few data exist in patients 
with severe exacerbations of COPD. The role of dynamic hyperinflation during exacerbations 
is unclear.
Methods: In a prospective, observational cohort study, we recruited patients admitted to hospital 
for AECOPD. The following measurements were performed upon admission and again after 
resolution (stable state) at least 42 days later: inspiratory capacity (IC), body plethysmography, 
dynamic hyperinflation by metronome-paced IC measurement, health-related quality of life 
and dyspnea.
Results: Forty COPD patients were included of whom 28 attended follow-up. The IC was low at 
admission (2.05±0.11 L) and increased again during resolution by 15.6%±23.1% or 0.28±0.08 L 
(mean ± standard error of the mean, p,0.01). Testing of metronome-paced changes in IC was 
feasible, and it decreased by 0.74±0.06 L at admission, similarly to at stable state. Clinical COPD 
Questionnaire score was 3.7±0.2 at admission and improved by 1.7±0.2 points (p,0.01), and 
the Borg dyspnea score improved by 2.2±0.5 points from 4.4±0.4 at admission (p,0.01).
Conclusion: Static hyperinflation is increased during severe AECOPD requiring hospitaliza-
tion compared with stable state. We could measure metronome-paced dynamic hyperinflation 
during severe AECOPD but found no increase.
Keywords: COPD, exacerbations of COPD, static hyperinflation, dynamic hyperinflation, severe 
acute exacerbations of COPD, COPD exacerbation, chronic obstructive pulmonary disease
Introduction
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause 
of death and predicted to become the third by 2020.1 Chronic airflow limitation is the 
defining characteristic of COPD. This limitation is caused by a mix of small airways 
disease and parenchymal destruction caused by chronic inflammation.1
Important in the clinical course of COPD are episodes with worsening of respi-
ratory symptoms from the stable state and beyond normal day-to-day variations, 
which require additional treatment.1 These exacerbations are associated with viral or 
bacterial airway infections in the majority of cases. Most exacerbations are of mild 
or moderate severity; only about 4% is categorized as severe.2 Severe exacerbations 
require hospital admission and are associated with increased mortality, morbidity, 
and health care costs.3–5
Apart from classification by severity (level of care) and infectious cause, little has 
been done to categorize exacerbations of COPD. Lopez-Campos and Agusti proposed 
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van geffen and Kerstjens
a dual axes system for categorizing and thereby for treating 
exacerbations, classifying exacerbations on an axis of severity 
and of infectious or eosinophilic inflammation.6 We believe 
that hyperinflation is another important component.7 
Hyperinflation is a better predictor of symptoms than most 
of our physiological parameters and also is a predictor of 
mortality in stable state.8,9 Furthermore different treatment 
strategies can be considered for hyperinflated patients.
Static hyperinflation is caused by entrapment of air 
during expiration, due to peripheral airway obstruction. 
This can be observed especially by destruction of alveolar 
attachments to small airways when the disease becomes 
more severe. Hyperinflation is characterized by increased 
functional residual capacity (FRC) and reduced inspiratory 
capacity (IC), resulting in increased dyspnea and limitation 
of exercise capacity.1,10–12
During tachypnea and exercise, hyperinflation can 
increase further and this is called dynamic hyperinflation. 
Dynamic hyperinflation is at least partly caused by a short-
ening expiration time, thus preventing patients to exhale 
completely and thereby causing air trapping.13–15 Dynamic 
hyperinflation of the lungs is known to limit exercise 
capacity in stable COPD and to impact on the perception 
of dyspnea.10,16,17
Only a few groups have attempted to study the course of 
hyperinflation during exacerbations. Parker et al included 
7 hospitalized patients and 13 outpatients with moderate 
exacerbations.18 They measured dyspnea and lung volumes 
with plethysmography. They found that after resolution of 
the exacerbation, some COPD patients showed an increase 
in IC (therefore decrease of hyperinflation) and improve-
ments in dyspnea. Stevenson et al studied admitted patients.19 
They measured symptoms with a Borg dyspnea score and 
volumes with spirometry but lacked direct measurements 
of hyperinflation for instance with body plethysmography. 
Although both studies reported dyspnea changes in subgroup 
analyses, these studies did not analyze the temporal relation 
between changes in symptoms and changes in hyperinflation. 
These two studies provide a strong direction of thoughts 
regarding static hyperinflation. However, they did not 
completely answer the question whether and to what degree 
static hyperinflation is present during severe acute exacerba-
tions of COPD and whether increased static hyperinflation 
is associated with more symptoms. Moreover, they did not 
assess dynamic hyperinflation.
This study was designed to confirm the presence of 
static hyperinflation in severe acute exacerbations and to 
analyze this in more depth with body plethysmography. 
Secondly, this study was aimed to assess dynamic hyperin-
flation. Furthermore, we hypothesized that improvement in 
dyspnea and quality of life during and after admission for 
an acute COPD exacerbation is closely related to changes in 
both static and dynamic hyperinflation.
Methods
subjects
Patients admitted with an acute COPD exacerbation were 
eligible for the study. The inclusion criteria we employed 
were as follows: 40 years or older, doctor’s diagnosis of 
COPD based on an incompletely reversible airflow obstruc-
tion defined as 1) a post-bronchodilator forced expiratory flow 
in 1 second (FEV
1
)/forced vital capacity (FVC) ,70% and 
2) post-bronchodilator FEV
1
,80% predicted. An exacerba-
tion was defined as a worsening of respiratory symptoms 
from the stable state and beyond normal day-to-day varia-
tions, which requires additional treatment. Excluded were 
patients with an X-ray-confirmed pneumonia, an indication 
for (non)invasive ventilation, admission to an intensive care 
unit, unstable angina pectoris or other clinically important 
cardiac comorbidity requiring admission to a cardiology ward. 
Additionally, we excluded patients who received any investi-
gational new drug within the last 4 weeks prior to admission. 
In concordance with the Dutch law and approved by our 
ethics committee (Medisch Ethische Toetsingscommissie 
Universitair Medisch Centrum Groningen), informed consent 
was obtained verbally within the first 24 hours of admis-
sion, and written informed consent was obtained in the first 
48 hours after the patient had had time and energy to read 
the paperwork. Data of patients who did not finally provide 
written informed consent were excluded from the study.
Design
This trial was registered in the World Health Organization 
approved International Clinical Trials Registry Platform, 
the Netherlands Trial Registry (NTR 4600). The study was 
conducted in the emergency room and pulmonary ward of a 
university teaching hospital in the Netherlands. Participants 
were tested after inclusion, prior to discharge, and after 
discharge in stable state at day 42 or later. Patients were 
allowed entry into the trial only once. Baseline characteristics 
were obtained, including X-ray, medication use, differential 
blood count, cultures and swabs for viral polymerase chain 
reaction. Treatment according to local guidelines included 
steroids (between 30 and 40 mg of prednisolone), antibiot-
ics, antivirals, oxygen and bronchodilators, all as needed. 
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Static and dynamic hyperinflation during severe AECOPD
about admittance and discharge were made by the treating 
physician who was not involved with the study team.
The primary outcomes were the changes in static hyper-
inflation (as measured by IC via spirometry [IC]) during 
resolution of the COPD exacerbation and changes in health-
related quality of life (primary: Clinical COPD Questionnaire 
[CCQ] and dyspnea [Borg score]).
The secondary outcomes were the changes in dynamic 
hyperinflation (as measured by IC during the metronome-
paced dynamic hyperinflation test) during resolution of the 
COPD exacerbation, changes in health-related quality of life 
by COPD Assessment Test and Modified Medical Research 
Council dyspnea score (mMRC), changes in other static 
hyperinflation volumes such as FRC, residual volume, total 
lung capacity (TLC) as well as changes in FEV
1
 and FVC 
during the resolution of the exacerbation.
Procedures
Spirometry was performed on working days during admit-
tance, post-medication; no pre-bronchodilator lung func-
tion was attempted. Once during admission and once in 
stable state, a body plethysmography (Jaeger MasterScreen, 
CareFusion) was performed as per European Respiratory 
Society (ERS)/American Thoracic Society (ATS) criteria.20 
When measuring static hyperinflation, the lung function 
technician aimed to measure the volumes at an elastic recoil 
pressure of the respiratory system of zero.
Metronome-paced hyperinflation was performed once 
during admission and stable state. Subjects were requested 
to breathe at a metronome-paced frequency of 40/minute 
during 30 seconds. Before increased pacing and immedi-
ately afterwards an IC maneuver was performed. Subjects 
were coached to maintain as much as possible a stable tidal 
volume. After at least 2 minutes, this measurement was 
repeated. Acceptability criteria of ,150 mL and/or ,5% 
were used (Oxycon Jaeger, CareFusion).
Pulmonary function testing during acute exacerbations 
is difficult for both patients and staff. If patients failed to 
produce a reliable value, the test was disregarded and was 
treated as missing value.
The diagnosis of an infection was established if either the cul-
ture or the nose swab tested positive. The swab used a polymerase 
chain reaction with primers for the 15 most common respira-
tory viruses in the Netherlands with a cutoff cycle threshold of 40.
statistical analyses
Data were analyzed with IBM SPSS 24. Normally distributed 
data with 2 time points were assessed with paired t-tests. 
Variables with multiple time points were first assessed by 
ANOVA to obtain an f ratio. If the f ratio indicated a sig-
nificant difference, a paired t-test was performed to assess 
the difference between admission and stable state. Unpaired 
t-tests were used to compare unpaired means. Bivariate cor-
relations by Pearson were calculated to assess correlations 
between two variables.
No formal power calculation was deemed possible since 
no relevant data were identified adequately reflecting our 
target population. Based on previous studies we anticipated 
dropouts; our ambition to perform reliable measurements 
based on the ATS/ERS criteria would only increase that. 
Aiming to measure a difference of 100 mL of change in 
IC, we roughly estimated the necessity of 25 evaluable 
patients. This estimated sample size was approved by the 
ethics committee.
Results
From September 2014 till April 2016 patients admitted to 
the respiratory ward from our tertiary university hospital 
with an acute exacerbation of COPD were recruited. Forty-
four patients provided their verbal informed consent upon 
admittance, 41 of them provided written informed consent 
within the first 24 hours; one of them developed a pneu-
mothorax and had to be excluded from the analysis, leaving 
40 subjects to be included in the study. Of 12 patients, no 
follow-up was obtained largely due to not being in stable 
state or not able to attend the follow-up. A flowchart of the 
study is provided in Figure 1. Baseline characteristics are 





44 provided verbal consent
7 did not provide verbal
informed consent
3 did not provide written
informed consent within 24 hours
1 developed a pneumothorax
and was withdrawn for safety
51 screened
1 died before reaching stable state
1 developed a cerebral
vascular event
1 did not reach stable state within
the study period
9 withdrew consent after discharge
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The primary endpoint, change in static hyperinflation 
measured by IC, showed an improvement of 0.28±0.08 L 
or 15.6%±23.1% (mean±standard error of the mean) from 
admission to stable state (p,0.01). This was accompanied 
by an improvement in CCQ of −1.7±0.2 points and in Borg 
score of −2.2±0.5 points. No correlation between the change 
in IC and change in CCQ (r=0.12, p=0.58) or change in Borg 
(r=−0.2, p=0.36) was found. The relative changes in the IC 
of each individual participant are plotted in Figure 2.
Of the secondary endpoints, static hyperinflation, mea-
sured as change in FRC by body plethysmography, improved 
significantly by 334±102 mL (p,0.01). Residual volume 
decreased significantly by 501±140 mL or as percentage 
predicted 22%±6% (p,0.01). As expected, TLC did not 
change during the resolution of the exacerbation. Dynamic 
hyperinflation (as measured by change in IC during a met-
ronome paced test) did not change significantly during the 
recovery from the exacerbation. Symptoms improved dur-
ing the resolution of the exacerbation in all questionnaires 
(Table 2). The change in dynamic hyperinflation did not 
correlate with the change in symptoms.
We compared patients with additional hyperinflation 
during the exacerbation with patients without additional 
hyperinflation (Table 3). The additionally hyperinflated group 
was defined as those patients whose IC improved 100 mL 
or more after recovery. The hyperinflated group had larger 
ICs and lower mMRC dyspnea scores (both significant) in 
stable state and additionally tendencies for greater improve-
ment in mMRC and Borg dyspnea scores (both nonsig-
nificant) during resolution. Interestingly, the group without 
additional hyperinflation during exacerbation had a higher 
number of eosinophils in peripheral blood at admission and 
a lower body mass index.
No difference in dynamic hyperinflation between the 
groups was detected. Subdividing the groups based on 
IC/TLC greater or lesser than 0.25 (instead of on decreased 
IC) yielded similar results, independent of whether exacerba-
tion or stable state data were used.
An exacerbation is often associated with a viral or 
bacterial airway infection. To assess the hyperinflation in 
relation to these infections, hyperinflation was analyzed in 
the subgroups based on the presence or absence of a viral or 
bacterial infection (Table 4). A significant change in static 
hyperinflation was observed in patients with a culture-posi-
tive bacterial infection, whereas no change was detected in 
the group without bacterial infection; these changes, how-
ever, did not statistically differ from one another (p=0.32). 
No difference was found in change in hyperinflation in 
patients with versus without a viral infection. No difference 
in dynamic hyperinflation was observed between any of the 
subgroups.
Discussion
This study showed a more complete picture of the course 
of static and dynamic hyperinflation in patients hospitalized 
Table 1 Baseline characteristics
Characteristics
number of patients 40
Age, years 66 (10)
sex, % male 52.5
Former smoker, % 70
Current smoker, % 30
number of pack-years 49 (35)
Body mass index, kg/m2 24.9 (4.8)
Post-bronchodilator FeV1 (% predicted) in stable state 51 (18)
Post-bronchodilator FeV1 (l) in stable state 1.3 (0.6)
Viral infection, % 47.5
Bacterial infection, % 42.5
Blood eosinophils, 10E9/L 0.15 (0.19)
Blood neutrophils, 10E9/L 8.6 (3.7)
ph on admission 7.43 (0.04)
PaO2 (kPa) on admission 8.6 (2.1)
PaCO2 (kPa) on admission 5.4 (1.0)
Antibiotics % of usage during admission 62.5
Antiviral medication % of usage during admission 7.5
Days to discharge 5 (2)
6-month readmission rate, % 40
Note: Values are presented as mean (sD) unless stated otherwise.






























Figure 2 The relative changes in the inspiratory capacity of each individual participant.
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Static and dynamic hyperinflation during severe AECOPD
for acute severe exacerbations of COPD, and its resolution 
toward stable state. Static hyperinflation is increased during 
acute severe exacerbations compared with stable state. 
We were able to measure dynamic hyperinflation during the 
exacerbation but found no further increase (more than the 
increase in static hyperinflation). No correlation between 
change in hyperinflation and symptoms was found.
COPD exacerbations are the main cause for admissions of 
COPD patients, and hospital-related mortality and morbidity 
in COPD patients is high. Nevertheless, little is known about 
the physiology of such exacerbations,3,21–24 and there is not 
really a universally accepted clinical definition of a COPD 
exacerbation nor of strict criteria when to admit.3,25 Although 
efforts have been made to better define and prevent exacerba-
tions in several recent trials, the treatment of an exacerbation 
in the hospital has remained mostly unchanged for the last 
2 decades.1,26–29
Two previous studies assessed static hyperinflation in 
the setting of an acute exacerbation of COPD. Our results in 
inpatients are in line with the results of the study of Parker 
et al (n=20) who studied mostly outpatients with less severe 
exacerbations than in the current study.18 The study of 
Stevenson et al (n=22) did study the same group of patients 
as the current study but provided only the change in IC as 
measured by spirometry, without the confirmation of body 
plethysmography. Our data confirm their results and extend 
them with additional measurements.19
Assessment of dynamic hyperinflation has not been 
described earlier in the setting of an acute severe exacerba-
tion of COPD to our knowledge. Patients were measured in 
this trial with a metronome-paced test aimed at changes in 
IC during tachypnea.12,30 No changes in dynamic hyperinfla-
tion between the exacerbation and stable state were found. 
Multiple explanations are possible for this result. It could 
indicate that patients with an exacerbation severe enough to 
require admission are limited by something else than hyperin-
flation, eg, airway resistance, mucus, hypercapnia or a change 
in ventilation/perfusion ratio. Another explanation could 
be that admitted patients already have a severely decreased 
inspiratory reserve capacity before admission and hardly have 
any room for further deterioration, as opposed to patients who 
do not need admission and in whom past data have shown 
decreasing ICs during exacerbations. Another explanation 
lies in the breathing frequency and tidal volume during the 
metronome-paced dynamic hyperinflation test. Due to ethical 
and practical concerns we imposed a frequency of 40, with a 
stable tidal volume during both tests. An alternative would 
have been to double their breathing frequency, which we 
deemed impossible for patients during severe exacerbations 
of COPD. A further increase in breathing frequency could 
Table 2 Recovery from severe acute exacerbations of chronic obstructive disease measured at admission, discharge and in stable state
Admission Discharge Stable state Change
Subjects n mean±SD Subjects n mean±SD Subjects n mean±SD Subjects n mean±SD
Spirometry
FeV1 (l) 39 1.05±0.52 37 1.10±0.52 28 1.35±0.57 28 0.28±0.37*
FVC (l) 36 2.61±0.85 36 2.98±0.85 28 3.29±0.88 26 0.58±0.68*
Static hyperinflation
IC (l) 36 2.06±0.65 34 2.13±0.67 28 2.40±0.70 27 0.28±0.41*
IC (% predicted) 36 74±20 34 76±20 28 88±20 27 10±17*
IC relative to admission (%) 36 100±0 31 104.4±17.8 27 115.6±23.1 27 15.6±23.1*
FrC (l) 28 4.86±1.64 25 4.36±1.29 22 −0.33±0.48*
rV (l) 28 3.76±1.34 25 3.09±1.08 22 −0.50±0.66*
TlC (l) 28 6.82±1.72 25 6.72±1.47
Dynamic hyperinflation
IC after metronome (l) 25 1.3±0.59 25 1.48±0.50
IC change after metronome (L) 25 −0.74±0.31 25 −0.82±0.43
Symptoms
CCQ 39 3.7±0.9 38 2.7±1.0 25 1.9±1.1 25 −1.7±1.1*
Borg 39 4.4±2.2 38 2.7±1.7 25 1.7±1.7 25 −2.2±2.4*
mMrC 39 3.4±1.0 38 3.2±0.9 25 2.4±1.3 25 −1.1±1.2**
CaT 25 26.2±7.0 25 20.8±6.0 25 16.5±9.0 25 −8.1±8.1*
Notes: Data are presented as mean ± standard deviation or number. *p,0.01 significant improvement from admission to stable state by paired t-test. **Significant 
improvement from admission to stable state by nonparametric Wilcoxon rank test.
Abbreviations: FeV1, forced expiratory flow in one second; FVC, forced vital capacity; IC, inspiratory capacity; FRC, functional residual capacity; RV, residual volume; 
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have allowed to find an additional dynamic hyperinflation 
component. Next, measurement of static hyperinflation 
depends on being able to measure at zero elastic recoil 
level.13 Although every attempt was made to achieve this, 
it is more difficult to achieve during severe exacerbations. 
If this elastic recoil cannot be achieved for the first FRC of 
the dynamic measurement, ie, before increasing the breathing 
frequency, dynamic hyperinflation (decrease in IC) during 
Table 3 Differences between patients with additionally increased hyperinflation during their exacerbation versus patients without 
additional hyperinflation 
Additional hyperinflation
(IC change .100 mL)
No additional hyperinflation
(IC change ,100 mL)
Number Mean±SD Number Mean±SD
number of patients 15 12
sex (number of males) 8 6
admission time (days)  4.87±1.68  5.00±1.91
Age (years)  65.87±5.79  62.92±9.48
BMI (kg/m2)  27.11±3.58  22.82±5.06*
Pack-years  55.42±39.23  49.00±41.18
ph (kPa)  7.42±0.05  7.44±0.03
PaCO2 (kPa)  5.43±0.85  5.35±0.63
PaO2 (kPa)  7.82±2.94  8.61±3.69
Neutrophils admission (10e9/L)  8.26±1.75  9.41±2.86
Eosinophils admission (10e9/L) 0.10±0.06  0.27±0.29*
Positive viral PCr 8 5
Positive bacterial culture 4 7*
Lung function
FeV1 in stable state (l)  1.43±0.66  1.24±0.48
Change in FEV1 (l)  0.40±0.26  0.18±0.44
IC during admission (L)  2.10±0.72  2.12±0.53
IC stable state (l)  2.68±0.74  2.03±0.49*
Change in IC (L)  0.58±0.28  −0.09±0.18*
FRC plethysmograph admission  4.63±1.56  4.70±1.55
FRC plethysmograph stable  4.23±1.29  4.64±1.32
Change in FRC (L)  −0.47±0.50  −0.22±0.41
RV plethysmograph admission (L)  3.65±1.39  3.43±1.11
RV plethysmograph stable state (L)  2.92±1.13  3.33±1.05
Change in RV (L)  −0.80±0.72  −0.17±0.37*
TLC plethysmograph stable state (L)  6.70±1.62  6.83±1.40
CO diffusion in stable state (mmol/min/kPA)  4.39±1.18  3.72±1.60
Dynamic hyperinflation admission (L)  −0.74±0.41  −0.70±0.23
Dynamic hyperinflation stable (L)  −0.86±0.53  −0.80±0.32
Symptoms
CCQ (admission)  3.4±0.7  4.0±0.9
CCQ (stable state)  1.6±1.0  2.3±1.2
Change in CCQ  −1.8±1.3  −1.6±0.8
CaT (admission)  22.4±7.3  28.1±6.9*
CaT (stable state)  14.3±7.6  17.3±9.8
Change in CAT  −7.5±7.8  −10.7±8.2
mMrC (admission)  3.1±1.1  3.8±0.5
mMrC (stable state)  1.8±1.2  3.0±1.2**
Change in mMRC  −1.5±1.3  −0.8±1.0
Borg (admission)  4.2±2.1  4.1±2.4
Borg (stable state)  1.2±1.2  2.1±2.2
Change in Borg  −2.6±1.6  −1.9±3.3
Notes: *p,0.05 in unpaired t-tests. **p,0.05 for nonparametric independent sample test. Data are presented as mean±standard deviation. Increased hyperinflation was 
defined as a difference in IC of at least 100 mL between exacerbation and stable state.
Abbreviations: BMI, body mass index; PCr, polymerase chain reaction; FeV1, forced expiratory flow in one second; IC, inspiratory capacity; FRC, functional residual 
capacity; RV, residual volume; TLC, total lung capacity; CCQ, Clinical COPD Questionnaire; CAT, COPD Assessment Test; mMRC, Modified Medical Research Council; 
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Static and dynamic hyperinflation during severe AECOPD
metronome pacing will be underestimated. Finally, one 
could discuss whether the test used in the current trial is the 
optimal standard to detect dynamic hyperinflation.13,31 Based 
upon ethical arguments, the study team chose not to perform 
the more commonly used and better validated exercise test 
during the acute distress of severe exacerbation requiring 
admission.
Hyperinflation might provide a target for therapeutic strate-
gies in patients with severe exacerbations. Patients admitted 
with a severe exacerbation of COPD are most commonly treated 
with short-acting bronchodilators via nebulizers. Long-acting 
bronchodilators, both anticholinergics and beta-2-mimetics, 
have been shown in stable state to provide larger reductions 
in hyperinflation compared to short-acting bronchodilators, 
alongside greater increases in flows.32–37 Long-acting broncho-
dilators, however, are not commonly available via nebulizers. 
A recent Cochrane review showed that after several decades 
of treatment with nebulizers, there is still no evidence to favor 
nebulizers over regular pressurised metered dose inhalers 
with good instruction.26 New studies should shed light on the 
potential of combined long-acting bronchodilators on reduc-
tion of hyperinflation during severe exacerbations requiring 
hospitalization. Such a trial could compare combined long-
acting bronchodilators in currently available pressurised 
metered dose inhalers or dry powder inhalers versus short-
acting bronchodilators by nebulizer, the latter being usual 
care in many hospitals. Based on the finding that hyperinfla-
tion is increased during exacerbations, we can speculate that 
the long-acting bronchodilators provide an early treatment 
for impending hyperinflation-predominant exacerbations of 
COPD, thus preventing some of them.38,39 Other strategies 
such as rehabilitation and noninvasive ventilation have been 
shown to reduce hyperinflation, while cognitive-behavioral 
strategies and perhaps even bronchoscopic lung volume reduc-
tion interventions could be further investigated as treatment 
of hyperinflation in selected patients during an acute event.7,40
Interestingly, patients who did hyperinflate during an 
exacerbation of COPD had higher ICs during stable state and 
fewer symptoms (CCQ, mMRC and Borg) both in stable state 
and during exacerbations. In other words, they had a better 
preserved inspiratory reserve capacity. This could perhaps 
also explain the lack of correlation between decrease in IC 
(worsening of hyperinflation) and increase in symptoms. 
One could argue that patients who do not hyperinflate dur-
ing an exacerbation are those patients who in stable state 
already have a flow limitation and are less able to increase 
their IC. This could result in more symptoms both during 
and after the exacerbation. This explanation is supported by 
the nonsignificant observation that symptoms improve more 
during resolution in patients with additional hyperinflation 
during exacerbations.
Increased static hyperinflation was found in patients with 
a bacterial or viral infection. The patients without a cultured 
bacterial infection showed no increased static hyperinflation 
during their exacerbations. These changes, however, do not 
significantly differ. This might suggest that the presence or 
absence of increased hyperinflation is related with an infec-
tious origin; however, more research and a larger sample 
size would be necessary before drawing conclusions from 
this subgroup analysis.
This study has several strengths but also has weaknesses 
that should be considered. A strong point of the study was 
that treatment decisions such as bronchodilator dose and 
discharge were made by the treating physician without influ-
ence from the trial team and without influence by the study 
measurement results. Another strong point of the trial is that 
we excluded patients with pneumonia. This will make the 
results from the trial more applicable toward exacerbations, 
since pneumonia might influence lung volumes. Patients 
who were in such distress that (non) invasive ventilation 
was required were also excluded in order to prevent bias 
due to inability to perform reliable pulmonary function tests. 
A weakness of the study is that it has been performed in only 
one center, potentially limiting the applicability of its results. 
Due to the severity of the exacerbation and disease, a relative 
high number of patients was not able or willing to provide 
Table 4 Differences in hyperinflation between exacerbations with and without a viral or bacterial infection
Static hyperinflation DH
IC admission (l) IC discharge (l) IC stable 
state (l)
IC change (l) p-value DH admission 
(IC change in l)
DH stable state 
(IC change in l)
p-value
Bacterial infection 2.3±0.7 2.5±0.7 2.7±0.8 −0.4 ,0.01* −0.8±0.3 −1.0±0.5 0.4
no bacterial infection 2.0±0.5 2.0±0.6 2.1±0.5 −0.2 0.29 −0.7±0.3 −0.7±0.3 0.9
Viral infection 2.1±0.7 2.3±0.7 2.4±0.7 −0.2 0.02* −0.8±0.3 −0.8±0.3 1.0
no viral infection 2.0±0.6 1.9±0.6 2.4±0.7 −0.3 0.03* −0.7±0.3 −0.8±0.5 0.2
Notes: Data are presented as mean±standard deviation. p-value: difference between admission and stable state by paired t-test. *p,0.05 in paired t-test. 
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reproducible pulmonary function tests or attend follow-up. 
Especially the intensive tests including the static and dynamic 
hyperinflation tests and spirometry repeatedly during the 
hospitalization were quite a burden on patients.
Static hyperinflation turned out to be an important feature 
of severe acute exacerbations of COPD in our population. We 
believe that this supports discussions whether the occurrence 
of hyperinflation should be incorporated in a new definition, 
since it is a common but not universal finding and opens a 
path toward a more precision medicine strategy in treatment. 
To our surprise, changes in hyperinflation were not directly 
correlated with symptoms although hyperinflated patients 
showed lower changes in symptoms. There must be other 
factors as well. Perhaps a model incorporating hyperinflation 
along with the current parameters of inflammation and respi-
ratory infections will help to work on a future definition.
In summary, this study measured changes in static and 
dynamic hyperinflation during acute severe exacerbations 
of COPD requiring hospital admittance. The increases in 
static hyperinflation were anticipated based on two earlier 
studies, only partially performed in hospital with less severe 
exacerbations. They have now been confirmed with body 
plethysmography. We were bold enough to attempt at mea-
suring dynamic hyperinflation during acute exacerbations 
in the hospital setting, but could not find a further increase 
over and above the change in static hyperinflation already 
induced by the exacerbation.
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